Abstract Number: 2458 • ACR Convergence 2025
Obecabtagene autoleucel (obe-cel), a CD19-targeting Autologous Chimeric Antigen Receptor T-cell Therapy (CAR T) with a fast off-rate binding domain, in Patients (pts) with Severe, Refractory Systemic Lupus Erythematosus (srSLE): Preliminary Results from the Phase I CARLYSLE Study
Background/Purpose: Pts with srSLE have limited remaining treatment options and represent a population with an unmet need. CD19 CAR Ts have potential for deep depletion…Abstract Number: 1851 • ACR Convergence 2025
Endotype Discovery in Systemic Lupus Erythematosus Using Multi-Omic Approaches: Toward Precision Insights into Cardiovascular and Renal Damage
Background/Purpose: Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder characterized by marked clinical variability, which complicates both diagnosis and treatment. Among its most severe…Abstract Number: 1530 • ACR Convergence 2025
The Renal Activity Index for Lupus Identifies and Predicts Complete Renal Remission or Absence of Kidney Involvement in Systemic Lupus Erythematosus
Background/Purpose: Effective, non-invasive disease activity and treatment response assessments are needed for patients with systemic lupus erythematosus (SLE), especially if associated with kidney disease, i.e.…Abstract Number: 1273 • ACR Convergence 2025
Effectiveness of IV Cyclophosphamide and Mycophenolate Mofetil in the Treatment of Pediatric Systemic Lupus Erythematosus with Lupus Nephritis
Background/Purpose: Lupus nephritis (LN) is more common in children (occurs in 50-82%) compared to adults. Cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are both treatment options…Abstract Number: 0655 • ACR Convergence 2025
Blood pressure remains elevated in patients initiating voclosporin with low baseline blood pressure: evidence from patients in routine clinical care
Background/Purpose: Hypertension was a common adverse event in RCTs testing voclosporin, an oral calcineurin inhibitor approved in 2021 to treat lupus nephritis (LN). In these…Abstract Number: 0851 • ACR Convergence 2025
Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis
Background/Purpose: Kidney survival is the ultimate treatment goal in lupus nephritis (LN), but long-term predictors remain understudied due to the need for extensive follow up.…Abstract Number: 2453 • ACR Convergence 2025
Belimumab Is Associated with Lower Risk of Progression to LN Compared with Standard of Care in Patients with SLE
Background/Purpose: LN develops in ~40% of patients with SLE and is associated with increased risk of morbidity, including end-stage kidney disease, and mortality. Belimumab, a…Abstract Number: 1847 • ACR Convergence 2025
Spatial transcriptomics reveals a complex microanatomic patterning of complement mediated inflammation and fibrosis in Class III pediatric lupus nephritis associated with local histologic injury
Background/Purpose: Lupus nephritis (LN) occurs in over 50% of patients with pediatric systemic lupus erythematosus (pSLE) and results in significant morbidity due to suboptimal kidney…Abstract Number: 1527 • ACR Convergence 2025
Lupus Nephritis Clinical Practice Guidelines: Critical Appraisal and Quality Comparison Using the AGREE II Tool
Background/Purpose: About a half of the patients with systemic lupus erythematosus (SLE) can present lupus nephritis (LN) throughout the course of their disease, representing one…Abstract Number: 1240 • ACR Convergence 2025
Serum Olink Proteomics Identifies Novel Mediators of Pain in Lupus Nephritis Patients Without Extrarenal Clinical Activity
Background/Purpose: For patients with lupus nephritis, active disease can be solely renal or include a range of extrarenal signs, such as arthritis or serositis, that…Abstract Number: 0654 • ACR Convergence 2025
Obinutuzumab Shows Promise in Lupus Nephritis Regardless of Baseline Serological Markers: An Exploratory Post Hoc Analysis of a Phase II Trial
Background/Purpose: Lupus nephritis (LN) is characterized by kidney inflammation. B cells play a central role in LN pathogenesis and type I interferon (IFN-I) pathway activation…Abstract Number: 0837 • ACR Convergence 2025
Risk of New Proteinuria in Next Ten Years in SLE
Background/Purpose: The current 2024 ACR Lupus Nephritis guidelines recommend checking the urine protein to creatinine ratio (UPCR) every 6-12 months. Early recognition of lupus nephritis…Abstract Number: 2452 • ACR Convergence 2025
Preliminary Safety, Efficacy, and Cellular Kinetics of CTA311, a CD19 Targeted Universal CAR-T Therapy, for Active Autoimmune Diseases
Background/Purpose: Systemic lupus erythematosus (SLE) and anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) are autoimmune conditions characterized by B cell activation, autoreactivity, and autoantibody production. CAR-T therapy…Abstract Number: 1846 • ACR Convergence 2025
Integrated spatial and single-cell profiling of treatment-naïve lupus nephritis biopsies
Background/Purpose: Lupus nephritis (LN) is characterized by kidney inflammation and leads to loss of kidney function. Depending on race/ethnicity, up to 60% of Systemic Lupus…Abstract Number: 1526 • ACR Convergence 2025
Guidance For Corticosteroid Tapering In Patients With Systemic Lupus Erythematosus: Results From An International Delphi Consensus Project
Background/Purpose: Despite guidelines for SLE emphasizing the importance of tapering corticosteroids (CS), detailed recommendations on how to taper are limited. The purpose of this modified…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 44
- Next Page »